



# Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024  
Grand Walkerhill Seoul, Korea

*"Pioneering the future of digestive diseases"*



SIDDS 2024

<b>Name</b>	Jung Won Chun
<b>Affiliation</b>	National Cancer Center
<b>Country</b>	Korea

## Educational Background

2010.3 ~ 2014.2: Seoul National University College of Medicine (Master course) (Doctor of Medicine)

2018.3 ~2023.8: Seoul National University College of Medicine Graduate School (Doctor of Philosophy)

## Professional Experience

2022.3~ current: Clinical Assistant Professor in National Cancer Center

2022.3~ current: Associate Scientist in National Cancer Center

2020.11~ 2022.2: Clinical Specialist in National Cancer Center

2019.3 ~ 2020.10: Clinical Fellowship in Seoul National University Hospital

2015.3 ~ 2019.2: Resident in Seoul National University Hospital

2014.3 ~ 2015.2: Internship in Seoul National University Hospital

## Main Scientific Publications

### First or corresponding author

• Annotation-Efficient Deep Learning Model for Pancreatic Cancer Diagnosis and Classification Using CT Images: A Retrospective Diagnostic Study, *Cancers*. 2023 ( 5.06 )

• Prolonged Patency of Fully Covered Self-Expandable Metal Stent with an Externally Anchored Plastic Stent in Distal Malignant Biliary Obstruction, *Endoscopy*, 2023;10.1055/a-2013-2034.

• Capecitabine and Temozolomide for Metastatic Intermediate to High-Grade Pancreatic Neuroendocrine Neoplasm: A Single Center Experience, *The Korean journal of internal medicine*, 2022;37(6):1216-1222 (3.165)

• A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma, *Therapeutic advances in medical oncology*, 2022 (5.485)

• Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach, *BMC cancer*, 2021 (4.43)

• RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin, *Journal of Clinical Medicine*. 2021 (4.242)

• Comparison of liquid-based cytology with conventional smear cytology for EUS-guided FNA of solid pancreatic masses: a prospective randomized noninferiority study, *Gastrointestinal Endoscopy*. 2019 (7.229)



## Co-author

- Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma. *Cancers*. 2022;14(22):5561. (6.575)
- Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade, *Cancers*; 14(18), 4445. 2022 (6.575)
- The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. *BMC Gastroenterol*. 2022;22(1):271 (3.067)
- Usefulness of Liquid-Based Cytology in Diagnosing Biliary Tract Cancer Compared to Conventional Smear and Forceps Biopsy. *Digestive Diseases and Sciences*. 2022;10.1007 (3.199)
- Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies, *Gut and Liver*. 2021 (4.519)
- Acetylsalicylic acid for metal stent in malignant distal common bile duct obstruction: A randomized controlled trial, *Hepatobiliary & Pancreatic Diseases International*. 2021 (3.78)
- Optimal timing of endoscopic retrograde cholangiopancreatography for acute cholangitis associated with distal malignant biliary obstruction. *BMC Gastroenterology*. 2021 (3.067)
- Efficacy of an internal anchoring plastic stent to prevent migration of fully covered metal stent in malignant distal biliary strictures: a randomized controlled study, *Endoscopy*. 2020 (7.341)
- Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach, *World J Clin Oncol*. 2020 (2.8)
- High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. *BMC cancer*. 2020 (3.2)
- The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort, *Cancer Medicine*. 2019 (3.4)